Literature DB >> 18196245

Sarcoidosis in patients with mixed connective tissue disease: clinical, genetic, serological and histological observations.

Peter Szodoray1, Zoltan Szollosi, Edit Gyimesi, Istvan Takacs, Gabriella Mekkel, Judit Vegh, Anna Szilagyi, Margit Zeher, Gyula Szegedi, Edit Bodolay.   

Abstract

The objective of this study was to investigate how the development of sarcoidosis influences the disease course of mixed connective tissue disease (MCTD). The cellular composition of MCTD-associated sarcoidosis granulomas was evaluated and also the disease-accompanying T-cell activation and alterations of the serum cytokine levels were measured before and after the therapy. The HLA-DR specific alleles were also assessed. We present two cases with MCTD coexisting sarcoidosis. Serum concentrations of Th1 and Th2 cytokines were assessed by ELISA. Peripheral blood CD3+ total T-cell numbers, CD4+ and CD8+ T-cell subset were determined by flow cytometry. Furthermore, hematoxylin-eosin staining and immunhistochemistry were performed for histological assessment. HLA-DR specific alleles were determined by using PCR-SSP. Elevated number of activated T-cells and high Th1 cytokine levels were detected, mainly IFN-gamma and TNF-alpha. Histologically, CD4+ and CD8+ T-cells were present in the sarcoidosis infiltrations. The haplotypes were to some extent dissimilar from the HLA-DR genotype from patients with MCTD, or sarcoidosis alone. Sarcoidosis enhances the activation of MCTD, based on the laboratory and clinical findings. Our results show that the inflammation is mainly in the effector phase, while granuloma formation is characteristic of the resolution phase of the disease. The assessment of the cytokine network in sarcoidosis-associated MCTD enables us to select the most effective, individualized therapy protocol for these patients.

Entities:  

Mesh:

Year:  2008        PMID: 18196245     DOI: 10.1007/s00296-008-0519-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  10 in total

Review 1.  Sarcoidosis.

Authors:  Robert P Baughman; Elyse E Lower; Roland M du Bois
Journal:  Lancet       Date:  2003-03-29       Impact factor: 79.321

Review 2.  The prognosis of mixed connective tissue disease.

Authors:  Ingrid E Lundberg
Journal:  Rheum Dis Clin North Am       Date:  2005-08       Impact factor: 2.670

Review 3.  ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders.

Authors:  U Costabel; G W Hunninghake
Journal:  Eur Respir J       Date:  1999-10       Impact factor: 16.671

4.  HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis.

Authors:  M Berlin; A Fogdell-Hahn; O Olerup; A Eklund; J Grunewald
Journal:  Am J Respir Crit Care Med       Date:  1997-11       Impact factor: 21.405

5.  Genome-wide search for sarcoidosis susceptibility genes in African Americans.

Authors:  M C Iannuzzi; S K Iyengar; C Gray-McGuire; R C Elston; R P Baughman; J F Donohue; K Hirst; M A Judson; M S Kavuru; M J Maliarik; D R Moller; L S Newman; D L Rabin; C S Rose; M D Rossman; A S Teirstein; B A Rybicki
Journal:  Genes Immun       Date:  2005-09       Impact factor: 2.676

Review 6.  Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

7.  Serum cytokine levels and type 1 and type 2 intracellular T cell cytokine profiles in mixed connective tissue disease.

Authors:  Edit Bodolay; Magdolna Aleksza; Péter Antal-Szalmás; Judit Végh; Péter Szodoray; Pál Soltész; Andrea Szegedi; Zoltán Szekanecz
Journal:  J Rheumatol       Date:  2002-10       Impact factor: 4.666

Review 8.  Sarcoidosis: immunology, rheumatic involvement, and therapeutics.

Authors:  J Barnard; L S Newman
Journal:  Curr Opin Rheumatol       Date:  2001-01       Impact factor: 5.006

9.  Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings.

Authors:  M A Burdt; R W Hoffman; S L Deutscher; G S Wang; J C Johnson; G C Sharp
Journal:  Arthritis Rheum       Date:  1999-05

10.  MICA4/HLA-DRB1*04/TNF1 haplotype is associated with mixed connective tissue disease in Swedish patients.

Authors:  Adla B Hassan; Liene Nikitina-Zake; Leonid Padyukov; Göran Karlsson; Manu Gupta; Ingrid E Lundberg; Carani B Sanjeevi
Journal:  Hum Immunol       Date:  2003-02       Impact factor: 2.850

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.